Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab

Kayo Tanita, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Yota Sato, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Since the efficacy of ipilimumab on nivolumab-resistant advanced melanoma is extremely low, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma is needed. Although several supportive therapies that enhance the antitumor immune response of anti-PD-1 antibodies have already been reported, unexpected immune-related adverse events were detected at the same time. In this report, we describe a patient with advanced melanoma treated with nivolumab followed by intensity-modulated radiotherapy, which might have triggered bullous pemphigoid (BP). Although several cases of BP developing in anti-PD-1 antibody-treated patients have already been reported, in this report, we shed light on the possible pathogenesis of BP developing in a patient treated with nivolumab through M2 macrophages.

Original languageEnglish
Pages (from-to)114-118
Number of pages5
JournalCase Reports in Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - 2018 Jan 19

Keywords

  • Advanced melanoma
  • Bullous pemphigoid
  • Intensity-modulated radiotherapy
  • Nivolumab

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab'. Together they form a unique fingerprint.

  • Cite this